ABG Lab, a growing boutique pharmaceutical R & D company with a strong focus on revolutionary skincare technology and aesthetic medicine.
Learn more about us!
ABG Lab’s vision is responsible for its rapid ascendancy to the upper echelons of anti-aging treatment providers. The ABG Lab mission statement is first and foremost to develop safe and optimal mesotherapy injections and anti-aging skincare technologies. Exclusive, proprietary formulations and Intradermal aesthetic injections administered to clientele at exclusive dermatology clinics throughout much of Europe.
ABG Lab’s anti-aging technology repertoire includes facial anti-aging injection treatments and proprietary skin care cosmetic products.
Among ABG LAB’s most successful mesotherapy technologies is its flagship Meso-Wharton P199®, the only Stem Cell Active Wharton Jelly peptide to reverse skin aging and restore health to damaged skin. Meso-Wharton P199® has demonstrated outstanding clinical results in over one million patients worldwide since its introduction in 2010.
Building on Meso-Wharton P199® success, ABG Lab two years later introduced the first epigenetic meso injection treatment Meso-Xanthin F199. Meso-Xanthin F199® provides what amounts to a cellular rejuvenation tonic for fibroblasts and epidermal skin cells. It keeps the cells young, healthy and operating at peak efficiency. Meso-Xanthin F199® reverses skin cell aging, protects against premature skin cell death by protecting vital intracellular defenses against the damaging effects of sun and chronological aging.
In 2014, ABG Lab launched MesoEye C71® and MesoSculpt C17®as part of its anti-aging arsenal to restore youthful facial beauty. MesoEye C71® focuses on the eye area, by effectively treating eye bags and under eye puffiness, dark circles and deep crows’ feet wrinkles. MesoSculpt C71® shrinks facial fat deposits in chin, jawline, and cheeks to restore a more youthful facial contour, restoring the classic facial triangle of beauty.